We advised Santen Pharmaceutical on certain aspects of the sale of its manufacturing facility in Tampere, Finland, to NextPharma.
We advised Japanese ophthalmology specialist Santen Pharmaceutical on certain aspects of the sale of its manufacturing facility in Tampere, Finland, to NextPharma, a leading European pharmaceutical contract development and manufacturing organization (CDMO).
The transaction is expected to be completed in the summer of 2019, with NextPharma taking over production of Santen products in the facility. Santen’s 181 employees at the site, who work in manufacturing and related operations, including quality control, quality assurance, IT and administration, will transfer to NextPharma.